{"preliminary_commentary":{"by_channel":{"youtube":11,"x_thread":5,"podcast":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06215118\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"MagnetisMM-30","nct_id":"NCT06215118","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=magnetismm-30-nct06215118. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Non-randomized elranatamab plus iberdomide","label":"Part 1 Dose Escalation","type":"EXPERIMENTAL"},{"description":"Randomized elranatamab plus iberdomide","label":"Part 2 Dose Randomization","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2028-10-15","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":100,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Elranatamab","otherNames":["PF-06863135"],"type":"DRUG"},{"name":"Iberdomide","otherNames":["CC-220","BMS-986382"],"type":"DRUG"}],"last_update":"2026-09-15","lead_sponsor":"Pfizer","official_title":"A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-11-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Number of participants with dose limiting toxicity (DLT)","timeFrame":"Cycle 1, about 28 days"},{"measure":"Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment","timeFrame":"Assessed from baseline up to 90 days after last dose of study treatment"}],"references":[],"start_date":{"date":"2024-02-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)","url":"https://clinicaltrials.gov/study/NCT06215118"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/magnetismm-30-nct06215118"}